MSLN CAR T cell therapy for advanced solid tumors
Treatments studied
Part of Cancer clinical trials.
This early-phase study tests a lab-made immune cell therapy (CAR T cells) that targets a protein called mesothelin (MSLN) in advanced or metastatic solid cancers. It may help your body better recognize and attack tumor cells, especially if standard first treatments did not work or are not available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You’re between 18 and 75 years old, and you’re expected to live more than 3 months
- Your cancer is advanced or has spread (metastatic), and it either failed first-line treatment or has no standard first treatment; your tumor must have mesothelin on at least 10% of cells
- You have at least one measurable tumor spot the team can track on scans
- You must provide a recent tumor sample (fresh is preferred, otherwise archived blocks) within 6 months and be willing to repeat biopsy if needed
- Your last cancer treatment finished more than 4 weeks ago, and side effects must be mild (grade 1 or less)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR-T) that targets specific proteins (CD73 and AXL) on tumor cells. It is for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if this therapy can shrink tumors or slow their growth.
This trial tests a new cell therapy called CHT102 for people with advanced solid tumors that have a certain marker (mesothelin). The treatment is for those who haven't responded to standard therapy or who don't have a standard first-line option.
This study tests a new type of immune cell therapy that seeks out and attacks cancer cells. It is for people with advanced solid tumors who have not improved with standard treatments and whose tumors show certain markers.
This trial is testing a new CAR-T cell therapy given as an injection for people with advanced or metastatic solid tumors that have stopped responding to standard treatments. CAR-T therapy uses your own immune cells to target and attack cancer cells. It may be an option if you have tried other treatments and they are no longer working.
This trial tests a new immune cell therapy called MSLN CAR-T for people with advanced solid tumors that have spread or cannot be removed by surgery. It may help if your cancer has not responded to standard treatment and tests positive for a protein called mesothelin (MSLN).
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.